Non-Small Cell Lung Cancer Treatment Regimens

Beschreibung

Understand U.S., Western Europe, and Japanese markets for first/second/third line treatment for NSCLC with regards to Stage (I-IV) and histology/biomarkers (squamous, non-squamous, EGFR mutant, and ALK mutant).
Shane Naki
Mindmap von Shane Naki, aktualisiert more than 1 year ago
Shane Naki
Erstellt von Shane Naki vor fast 10 Jahre
14
0

Zusammenfassung der Ressource

Non-Small Cell Lung Cancer Treatment Regimens
  1. Systemic Regimens by Country
    1. United States (2015)
      1. Carboplatin + Alimta + Avastin
        1. Carboplatin + paclitaxel
          1. Xalkori
            1. Tarceva
              1. United States
                1. docetaxel
                  1. docetaxel
                    1. Gilotrif
                      1. Zykdaia
                        1. United States
                          1. Opdivo
                            1. Tarceva
                              1. Opdivo
                                1. Opdivo
                            2. Western Europe (2015)
                              1. cisplatin + gemcitibine
                                1. Cisplatin + Alimta
                                  1. Tarceva
                                    1. Xalkori
                                      1. Western Europe
                                        1. docetaxel
                                          1. docetaxel
                                            1. cisplatin + Alimta
                                              1. Xalkori
                                                1. Western Europe
                                                  1. Vinorelbine
                                                    1. Vinorelbine
                                                      1. Vinorelbine
                                                        1. vinorelbine
                                                    2. Japan (2014)
                                                          1. Treatment Line
                                                            1. 1
                                                              1. Squamous
                                                                1. Non-Squamous
                                                                  1. EGFR mutant
                                                                    1. ALK Mutant
                                                                2. 2
                                                                  1. 3
                                                                    1. Squamous
                                                                      1. Non-Squamous
                                                                        1. EGFR Mutant
                                                                          1. ALK Mutant
                                                                    2. Squamous
                                                                      1. Non-Squamous
                                                                        1. EGFR Mutant
                                                                          1. ALK Mutant
                                                                Zusammenfassung anzeigen Zusammenfassung ausblenden

                                                                ähnlicher Inhalt

                                                                QuintilesIMS Institute 2016: Outlook for Global Medicine through 2021
                                                                Shane Naki